Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.54 |
| ▸ | MLNR | O43193 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935417 | 0.92 | SPPL2A (0.53) | SPPL2A | |
| SCHEMBL14113255 | 0.92 | SPPL2A (0.53) | SPPL2A | |
| SCHEMBL4911599 | 0.92 | SPPL2A (0.53) | SPPL2A | |
| SCHEMBL9082056 | 0.90 | SPPL2A (0.55) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL5172203 | 0.89 | SPPL2A (0.54) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL5173172 | 0.87 | SPPL2A (0.52) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL5172255 | 0.87 | SPPL2A (0.49) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL6525403 | 0.85 | SPPL2A (0.61) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL6262004 | 0.84 | MLNR (0.49) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL9083184 | 0.83 | MLNR (0.47) | SPPL2AMLNRABCB11LMNACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804428-B1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | SEARLE LLC (US) | 2007-12-26 | — | — | EP | claimed |
| EP-1586558-A2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors | G.D. Searle LLC. (US) | 2005-10-19 | — | — | EP | claimed |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-04-01 | — | — | US | claimed |
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-01-16 | — | — | US | claimed |
| US-6384036-B1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-05-07 | — | — | US | claimed |
| WO-1996022287-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | claimed |
| EP-0804428-B1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | SEARLE LLC (US) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | SPPL2A 659/4885MLNR 3973/4885ABCB11 607/4885 |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | SPPL2A 659/4885MLNR 3973/4885ABCB11 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.